

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

**POLL RESULTS OF
THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
HELD ON TUESDAY, 7 NOVEMBER 2023**

References are made to the notice and circular (the “**Circular**”) of the 2023 second extraordinary general meeting (the “**EGM**”) of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) dated 13 October 2023. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the proposed resolutions as set out in the notice of the EGM were duly passed by way of poll at the EGM held on 7 November 2023.

As at the record date of the EGM, the issued share capital of the Company was 935,552,687 shares (the “**Shares**”) (comprising 625,721,470 A Shares and 309,831,217 H Shares). Therefore, Shareholders holding a total of 935,552,687 Shares (or the authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM.

To the best of the Directors’ knowledge, information and belief and having made all reasonable enquiries, there were no restrictions on any Shareholders for casting votes on the resolutions proposed at the EGM and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM. No Shareholders are required under the Hong Kong Listing Rules to abstain from voting on the resolutions at the EGM.

ATTENDANCE OF THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies	61
Including: Number of A Shareholders and authorized proxies	60
Number of H Shareholders and authorized proxies	1
Total number of Shares carrying voting rights (Shares)	457,228,552
Including: Total number of A Shares carrying voting rights held by A Shareholders and authorized proxies (Shares)	271,216,587
Total number of H Shares carrying voting rights held by H Shareholders and authorized proxies (Shares)	186,011,965
Percentage of the total number of Shares carrying voting rights (%)	48.87%
Including: Total number of Shares carrying voting rights held by A Shareholders and authorized proxies as a percentage of the total number of Shares carrying voting rights (%)	28.99%
Total number of Shares carrying voting rights held by H Shareholders and authorized proxies as a percentage of the total number of Shares carrying voting rights (%)	19.88%

POLL RESULTS OF THE EGM- SEPCIAL RESOLUTIONS

No.	Resolutions	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting
1	To consider and approve the draft and summary of the third phase ownership scheme under the Medium to Long-term Business Partner Share Ownership Scheme of the Company.	Total	457,228,552	423,532,295	92.6303%	33,602,957	7.3493%	93,300	0.0204%
		A Shares	271,216,587	260,429,758	96.0228%	10,784,629	3.9764%	2,200	0.0008%
		H Shares	186,011,965	163,102,537	87.6839%	22,818,328	12.2671%	91,100	0.0490%
2	To consider and approve the administrative measures of the third phase ownership scheme under the Medium to Long-term Business Partner Share Ownership Scheme of the Company.	Total	457,228,552	423,532,295	92.6303%	33,602,957	7.3493%	93,300	0.0204%
		A Shares	271,216,587	260,429,758	96.0228%	10,784,629	3.9764%	2,200	0.0008%
		H Shares	186,011,965	163,102,537	87.6839%	22,818,328	12.2671%	91,100	0.0490%
3	To consider and approve the authorization to the Board to deal with matters regarding the third phase ownership scheme under the Medium to Long-term Business Partner Share Ownership Scheme of the Company.	Total	457,228,552	423,532,295	92.6303%	33,602,957	7.3493%	93,300	0.0204%
		A Shares	271,216,587	260,429,758	96.0228%	10,784,629	3.9764%	2,200	0.0008%
		H Shares	186,011,965	163,102,537	87.6839%	22,818,328	12.2671%	91,100	0.0490%
As votes cast for the above special resolutions were more than two-thirds of the valid voting rights of Shareholders (including authorized proxies) present at the EGM, the above special resolutions were duly passed as the special resolutions.									

Grant Thornton (Special General Partnership), the auditor of the Company, acted as the scrutineer for the vote-taking at the EGM. The Company's PRC legal advisors, D&S Law Firm (廣東德賽律師事務所), two Shareholders' representatives and a representative of the supervisors of the Company also jointly acted as the scrutineers for the vote-taking of the poll at the EGM.

LEGAL OPINION ISSUED BY LAWYERS

Delegated lawyers from D&S Law Firm witnessed the EGM and issued the "Legal Opinions of D&S Law Firm on the EGM of Livzon Pharmaceutical Group Inc. (《廣東德賽律師事務所關於麗珠醫藥集團股份有限公司二零二三年第二次臨時股東大會的法律意見書》)", certifying that: "The procedures for convening and holding the EGM are in compliance with the requirements of laws, regulations and Articles of Association; the qualifications of personnels who attended the EGM, the qualifications of the conveners, and the voting procedure of the EGM are legal and effective; the voting results of the resolutions at the EGM, are legal and effective."

SPECIAL NOTICE

There was neither objection to the proposed resolutions of the EGM, nor changes to the resolutions of the previous general meetings at the EGM.

ATTENDANCE RECORD OF THE DIRECTORS

All Directors have attended the Meetings either in person or through electronic means.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
7 November 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*